Gapping down
In reaction to earnings/guidance:
- BAC -2.3%, WFC -1.6%, ASML -1.2%
Other news:
- CYCN -41.7% (announces top-line results from its STRONG-SCD study of olinciguat, an investigational, orally-administered, once daily, vascular sGC stimulator for the potential treatment of sickle cell disease)
- SRNE -11.5% (R&D investor update on COVID-19 last night)
- LAZY -7.7% (stock offering)
- OCUL -7.5% (prices offering of 7.18 mln shares of common stock at $9.75 per share)
- RPRX -4% (stock offering)
- LOOP -2.2% (responds to "inaccurate" Hindenburg Research report)
- SPNS -2.1% (stock offering)
- ACGL -2% (provides update on catastrophe losses)
- KDMN -1.1% (to move from NYSE to Nasdaq on Oct 26)
Analyst comments:
- ALB -2.6% (downgraded to Underperform from Sector Perform at RBC Capital Mkts)
- WIT -2.6% (downgraded to Hold from Buy at Investec)
- PGRE -2.1% (downgraded to Underperform from Neutral at BofA Securities)
- NVTA -1.4% (downgraded to Neutral from Overweight at JP Morgan)
- STZ -0.8% (downgraded to Neutral from Overweight at Atlantic Equities)
- DOYU -0.6% (downgraded to Neutral from Overweight at JP Morgan)